Business context and reporting period
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule medicines using a structure-based drug discovery platform, with an initial focus on G-protein-coupled receptors. This unaudited Form 10-Q covers the three months ended March 31, 2023; comparative figures are for the three months ended March 31, 2022. The company has no approved products and has generated no product revenue.
Financial performance and position
Amounts below are in U.S. dollars; income statement and cash flow figures cover the quarter, while balance sheet figures are as of the stated dates.
| Metric | Q1 2023 | Q1 2022 / prior date |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $13.1 million | $8.5 million |
| General and administrative expense | $6.5 million | $4.5 million |
| Total operating expenses / operating loss | $19.6 million / $(19.6) million | $13.0 million / $(13.0) million |
| Interest and other income (expense), net | $1.7 million | $(0.1) million |
| Net loss | $(18.0) million | $(13.1) million |
| Basic and diluted loss per share | $(0.25) | $(1.44) |
| Net cash used in operating activities | $20.3 million | $13.5 million |
| Cash and cash equivalents | $126.5 million | $26.1 million at Dec. 31, 2022 |
| Short-term investments | $114.4 million | $64.8 million at Dec. 31, 2022 |
| Total current assets / current liabilities | $246.2 million / $11.0 million | $93.1 million / $13.0 million at Dec. 31, 2022 |
| Total assets / accumulated deficit | $247.4 million / $(134.9) million | $97.8 million / $(117.0) million at Dec. 31, 2022 |
Operating margins are not meaningful given the absence of revenue. The filing reports no outstanding debt at March 31; total liabilities were $11.0 million, including current operating lease liabilities. Lease obligations were approximately $0.2 million through October 2023.
Material changes and notable items
- Research and development expense increased 55%, chiefly from advancing the GLP-1R program and other research, and higher employee costs, including share-based compensation. GSBR-1290-related expense rose to $7.9 million from $3.3 million; ANPA-0073 expense declined to $0.5 million from $2.0 million.
- General and administrative expense increased 46%, reflecting personnel and professional-service costs associated with growth and public-company operations.
- Net loss increased by $4.9 million year over year, partly offset by $1.7 million of interest and other income versus a small expense a year earlier. Higher interest income reflected increased cash and investment balances and interest rates.
- The February 7, 2023 IPO raised approximately $166.7 million net of underwriting discounts, commissions and estimated offering costs. All preferred shares converted into ordinary shares at IPO closing. Cash, cash equivalents and short-term investments totaled $240.9 million at quarter-end, compared with $90.8 million at year-end.
- Financing activities provided $169.7 million, primarily from the IPO; investing activities used $49.0 million, mainly for net purchases of short-term investments.
- Share-based compensation was $2.5 million, compared with $0.6 million in Q1 2022, including $1.5 million related to China-based employee options triggered by the IPO.
Outlook, commentary and risks
- Management states that, under its current business plan, quarter-end cash and investments are expected to fund operations through at least 2025. The financial-statement note separately says resources are sufficient for at least 12 months from issuance. Both estimates depend on assumptions and spending needs could cause funds to be used sooner.
- The company expects significant and increasing expenses and operating losses as it advances clinical programs, expands its pipeline, hires staff and bears public-company costs. It expects to need substantial additional capital; future financing could dilute shareholders or require concessions on collaboration or licensing terms.
- GSBR-1290: Phase 1b multiple-ascending-dose dosing in healthy overweight subjects was completed in March 2023. Management expected topline Phase 1b data and Phase 2a data in the second half of 2023, with the Phase 2a proof-of-concept study in type 2 diabetes and obesity expected to start in that half.
- ANPA-0073 completed Phase 1 single- and multiple-ascending-dose studies in 2022 and was generally well tolerated. The company planned additional preclinical work and a formulation-bridging pharmacokinetic study in Australia. For its LPA1R program, a development candidate was selected in January 2023, with a first-in-human study expected in 2024.
- A 13-week nonhuman-primate toxicology study of GSBR-1290 observed low-to-moderate liver necrosis across all dose groups, including controls. The company said the findings were not attributed to GSBR-1290, but noted that the FDA could disagree or require action, potentially delaying development.
- Key execution risks include early-stage clinical and regulatory uncertainty, trial enrollment and safety, reliance on third parties for research and clinical work, and dependence on a single-source supplier, WuXi STA, for active ingredients and drug product. The company also identifies China-related regulatory and geopolitical risks and uncertainty around Australian research and development tax credits.
- Disclosure controls were assessed as ineffective at March 31, 2023 due to continuing material weaknesses involving staffing and financial-reporting control environment, segregation of duties, and IT general controls. Management is implementing remediation; the weaknesses had not been remediated and could allow material misstatements not to be prevented or detected timely.
- The filing reports no material legal proceeding or material indemnification claim. It also identifies potential market overhang: substantially all IPO shareholder lock-ups were scheduled to expire August 1, 2023, subject to possible earlier release.
- After quarter-end, on May 10, 2023, certain investors exchanged 7,410,518 ordinary shares one-for-one for newly designated non-voting ordinary shares. The exchange did not change total shares outstanding; conversion rights are subject to beneficial-ownership limits.
Most important facts for investors to verify
- Whether GSBR-1290’s Phase 1b results and Phase 2a timing matched management’s stated second-half 2023 expectations, and the implications of the animal-study liver findings.
- Whether cash and short-term investments continue to support the stated runway through at least 2025 as clinical spending and public-company costs rise.
- Progress and effectiveness of remediation of the disclosed internal-control material weaknesses.
- Clinical supply continuity and dependence on WuXi STA and other outside research, trial and manufacturing providers.
- Share supply following IPO lock-up expirations and the ownership and conversion terms of the non-voting shares.